PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Orgasm”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 145 records · Page 8Linked to original sources
PubMed1992

Does the CAT technique enhance female orgasm?

The following is a report of The Human Sexuality Program of the New York Hospital-Cornell Medical Center to personally replicate Edward W. Eichel's claims that his Coital Alignment Technique (CAT) enhances and increases female coital orgasms and mutual orgasms. We failed to replicate these claims. However, it was the consensus of the group that within the context of sex therapy, the CAT technique may have merit in certain clinical situations, and as such deserves to be further evaluated.

Coitus↗
PubMed1993

A comparative study using orgasm consistency training in the treatment of women reporting hypoactive sexual desire.

In an experimental study, a standard group intervention for treating women with hypoactive sexual desire was compared to a standard group intervention plus orgasm consistency training. Specificity of sexual change following treatment was assessed in 39 women with hypoactive sexual desire disorder who completed either treatment. Following treatment, women in both groups reported significantly positive sexual changes on two of the four measures of sexual behavior. Compared with the women receiving only standard treatment, the women who also received orgasm consistency training reported greater sexual arousal and sexual assertiveness at posttreatment and at three-month and six-month follow-up evaluations and greater sexual satisfaction at the six-month follow-up. Implications for these findings, study limitations, and future research directions are explored.

Female↗
PubMed1984

Inhibited sexual desire and orgasmic dysfunction in women.

Desire phase dysfunction and orgasmic dysfunction are frequently brought to the attention of the gynecologist. While a variety of psychosocial and organic factors may be involved, the clinician can be helpful in a number of ways. Specific techniques of sexual counsel for both ISD and orgasmic dysfunction have been presented. Recognition and treatment of sexual dysfunction can be a somewhat time-consuming but rewarding aspect of comprehensive women's health care.

Alcoholism↗
PubMedDate not supplied

Orgasmic headache with transient basilar artery vasospasm.

A 36-year-old man without significant past medical history presented with recurrent explosive headache at the time of orgasm. Magnetic resonance angiography showed focal mid-basilar artery narrowing. Despite receiving no specific therapy, the patient's headaches and vascular narrowing had resolved completely on follow-up six months later. While a number of pharmacologic agents have been proposed to be of benefit in orgasmic headache, this case suggests that spontaneous resolution may also occur.

Adult↗
PubMedDate not supplied

Dissecting aneurysm of the basilar artery as a cause of orgasmic headache.

A 39-year-old woman experienced recurrent, severe bursting headache which was abruptly developed at the time of orgasm. Both magnetic resonance angiography and conventional angiogram of the brain confirmed dissecting aneurysm of the basilar artery. After the neuroradiological intervention using a stent was performed, she has been totally free of the orgasmic headache during the follow-up period for about one year.

Adult↗
PubMedDate not supplied

Orgasmic epilepsy.

We studied a 41-year-old woman who had nocturnal somatosensory seizures followed by orgasm. The interictal EEG showed discrete left central parietal region paroxysmal activity that markedly increased during sleep. Eight electroclinical seizures were recorded during sleep polygraphic recording. Orgasms occurred coinciding with generalization of paroxysmal activity. No abnormalities were found on serial neurologic examination or computed tomography scan. The attacks were completely controlled with antiepileptic drugs.

Adult↗
PubMed1976

Behavioural treatment of orgasmic dysfunction: a controlled study.

Twenty-two anorgasmic women received 20 sessions of a multiple-technique behavioural therapy. The design included blind ratings by two independent assessors, multiple assessment instruments, and a waiting list control group. Treatment was significantly better than no treatment in terms of: (1) the percentage of patients experiencing orgasm during at least 50 per cent of sexual relations; (2) the percentage of women reporting satisfactory sexual relations at least 50 per cent of the time; (3) patients' ratings of positive reactions to various sexual behaviours; and (4) assessors' global clinical ratings. Significant improvement was also noted on the MMPI, IPAT, and Symptom Check List. Improvement was maintained at a follow-up average 9 months later. These results support the impression that a behavioural approach offers much promise in treating female orgasmic dysfunction.

Adult↗
PubMed2002

Orgasmic aura originates from the right hemisphere.

The authors present a patient with right mesiotemporal epileptogenic region who experienced orgasmic epileptic aura. Twenty-two similar published cases were also evaluated. Among 15 patients with unilateral EEG foci, 13 (87%) had right and 2 (13%) had left focus. All of the nine patients who had sufficient data on ictal onset area had right-sided seizure onset. The authors suggest that orgasmic aura is an ictal lateralizing sign to the right hemisphere.

Adult↗
PubMedDate not supplied

[Treatment with risperidone of a case of spontaneous orgasm].

A case report is presented of a patient who had spontaneous orgasms following treatment with clomipramine and were successfully treated with risperidone. The relationship with previous reports on drug-induced spontaneous orgasm is analyzed.

Adult↗
PubMedDate not supplied

[Time factors and trends in the onset of the menarche, sex maturation and experience of orgasm in a questionnaire administered to 971 women in Vojvodina].

A questionnaire and interview of 971 women aged 15-80 years or more from three Voivodina communes (Becej, Veternik, Mali Idos) have supplied the following information: the arithmetic mean of the age of women during menarche is 13.459 +/- 1.523 years, the median being 13.872 years. Menarche appears earlier in the town (13.334 +/- 1.373) than in villages (13.668 +/- 1.61). The arithmetic mean of menarche recedes towards younger age groups (y = 12.90 +/- 0.106; r = 0.890, p less than 0.01), so that below 20 years is 1.4 years, and this is more pronounced in the town than on villages. The arithmetic mean of the age of women at sexarche (the first sexual intercourse) is 19.088 +/- 2.495 years, and the median is 18.964. The interval between the arithmetic mean of menarche and sexarche is 5.6 years, smaller in the urban (5.0) than in the rural environment (6.4). Sexarche recedes towards younger age groups (y = 18.136 +/- 0.130; r = 0.540), more intensively than the acceleration of menarche. In the course of their sexual life, 16.4% of women rarely experienced orgasm, 11.2% never did. The experience of orgasm "rarely" or "never" is statistically significantly more frequent in women over 40 years of life in relation to younger women (X2 = 6.893, p less than 0.01).

Adult↗
PubMedDate not supplied

Self-perceived differences in the female orgasmic response.

This investigation was concerned with perceived differences between orgasms experienced via masturbation, petting, and sexual intercourse and the relationship of such differences, if any, to sexual satisfaction. An anonymous questionnaire was distributed to registered nurses in fifteen states concerning sexual attitudes, sexual behavior and the female sexual response. Although 76% of these respondents reported perceived differences between orgasms experienced via masturbation, petting, and sexual intercourse, no differences were found between respondent groups for either physiological or psychological sexual satisfaction. Several other variables were identified which affected perceived levels of sexual satisfaction. A clear understanding of these findings should be helpful in counseling patients with sexual problems.

Adult↗
PubMed1983

Inhibited female orgasm resulting from psychotropic drugs. A clinical review.

Female orgasm inhibition associated with psychotropic agents was reported ten years after the first report of ejaculatory disturbance in the male resulting from psychotropic drugs. To date, the psychotropic agents that have been reported to inhibit female orgasm include antipsychotic agents (thioridazine and trifluoperazine), monoamine oxidase inhibitors (phenelzine, isocarboxazid and tranylcypromine) and tricyclic antidepressants (amoxapine, clomipramine and amitriptyline). As awareness of this sexual side effect of psychotropic drugs grows, more drugs undoubtedly will be added to the list. Physicians should be alert to the underreporting of sexual side effects by female patients and should solicit such information from them.

Adult↗
PubMed1993

[Multiple orgasms in women].

Two hundred women treated for neurotic disorders and 100 female health professionals and counselors were investigated by means of a questionnaire to establish, whether they can have two or more consecutive orgasms. Multiple orgasms were reported to occur mostly or often in 14% of neurotics and in 39% of the health professionals. Our results in female neurotics are in agreement with the classical data of Kinsey et al. (1953) and with the recent data of Hubalek (1986), who investigated 121 women presenting for suspected sterility. Our results in health professionals and counselors are close to the data of Darling et al. (1991) in a sample of 805 American female nurses. It seems that capacity for multiorgasmic experience in women is higher than was generally acknowledged previously. It is possible that nurses, medical doctors and psychologists use their better knowledge of sexuality in their sexual activities to obtain more effective stimulation for fuller use of their sexual capacity.

Female↗
PubMed1993

[Sexual stimulation and the female orgasm].

Questionnaire data regarding mode of sexual stimulation were collected in 200 women treated for neurotic disorders and 100 female health professionals and counselors. Clitoral stimulation was the source of female orgasm in 90% of subjects, while three quarters achieved orgasm also by means of vaginal stimulation. The anterior wall of the vagina seemed to be slightly more important than the posterior one. One third of the respondents reported effective stimulation in the depth of the vagina with cervical tapping. Stimulation in the area corresponding to the alleged G spot was acknowledged as effective by 10 to 20%. The sexual responsiveness of neurotic patients was generally somewhat lower than responsiveness of health professionals and counselors.

Female↗
PubMedDate not supplied

Are our definitions of women's desire, arousal and sexual pain disorders too broad and our definition of orgasmic disorder too narrow?

Since each individual female sexual dysfunction is complex, it is necessary to subtype them in addition to dividing them into life-long or acquired disorder. The complexity of women's sexual arousal necessitates appreciation of a number of different types of arousal disorders that vary not only in etiology but also in management. The coexistence of sexual arousal and sexual desire, which develops during a sexual experience, explains the frequent comorbidity of arousal and desire disorders. Subtyping of hypoactive sexual desire disorder allows analysis of lack of receptivity and of any marked loss of the traditional markers of sexual desire over and beyond a normative lessening with relationship duration. Dyspareunia and vaginismus require further analysis prior to any definitive therapy. The definition of orgasmic disorder needs to include loss of orgasmic intensity and the possibility of coincident arousal disorder.

Affect↗
PubMed2004

Vardenafil improves patient satisfaction with erection hardness, orgasmic function, and overall sexual experience, while improving quality of life in men with erectile dysfunction.

PURPOSE: The North American Pivotal Trial was designed to investigate the efficacy and safety of vardenafil in males with erectile dysfunction (ED). MATERIALS AND METHODS: In this randomized, double-blind, placebo-controlled, multicenter, fixed-dose, parallel group, 6-month study, vardenafil at three doses (5 mg, 10 mg, and 20 mg) was compared to placebo with the primary efficacy variables being the International Index of Erectile Function (IIEF) Erectile Function (EF) domain score and per patient diary response success rates for penetration and maintenance of erection through completion of intercourse. Additional efficacy variables included IIEF domain scores measuring intercourse satisfaction, orgasmic function, sexual desire, and overall satisfaction. Diary entries for overall per patient satisfaction rates for hardness and sexual experience were also measured. Improvements in quality of sexual life were assessed using the Fugl-Meyer quality of life (QoL) questionnaire. RESULTS: Compared to placebo, patients taking 10 mg and 20 mg doses of vardenafil showed statistically significantly greater improvement in IIEF domain scores measuring intercourse satisfaction (10.3 and 10.3 vs. 7.7), orgasmic function (7.1 and 6.9 vs. 5.3), overall satisfaction. (7.1 and 7.1 vs. 5.2) for vardenafil 10 mg and 20 mg vs. placebo, respectively, at last observation carried forward (LOCF). Vardenafil 5 mg was statistically significantly better than placebo for the secondary IIEF domain variables of intercourse satisfaction (8.9 vs. 7.7) and overall satisfaction (6.3 vs. 5.2) for vardenafil vs. placebo, respectively, at LOCF. Per patient satisfaction rates for the secondary diary variables measuring erection hardness (38%, 52%, 58% and 18%) and overall satisfaction (45%, 58%, 62% and 23%) were dose dependent and statistically significantly superior for vardenafil at 5 mg, 10 mg and 20 mg compared with placebo, respectively. Patients' answers to the Fugl-Meyer QoL questionnaire assessing improvement in sexual life also indicated statistically significant superiority for all doses of vardenafil vs. placebo treatment. The most frequent adverse events (AE) in the 5 mg, 10 mg, and 20 mg of vardenafil and placebo groups, respectively, were: headache (10%, 22%, 21% and 4%), flushing (5%, 10%, 13% and 0%), dyspepsia (1%, 4%, 6% and < 1%), and rhinitis (9%, 14%, 17% and 5%). Most AEs were mild or moderate in severity and transient in nature. CONCLUSION: Vardenafil was superior to placebo for IIEF domain scores, per patient success rates for diary questions, and assessment of quality of sexual life, in a broad range of patients with ED irrespective of etiology or severity. Vardenafil was generally well tolerated, with most AEs being mild or moderate in severity and transient in nature.

Adult↗
PubMed1976

Electroencephalographic laterality changes during human sexual orgasm.

Left and right parietal EEGs were recorded while seven subjects experienced sexual climax through self-stimulation. EEG data were quantified by continuous cumulated measurements of the integrated areas of EEG recording during successive 1-sec epochs. In eight out of 12 experiments, this measure revealed a statistically significant change in laterality. Controlled replications with two of the original subjects obviated the possibility that two potential sources of artifact (hand used for masturbation and gross body movements) accounted for the changes. While previous research has focused on vasomotor and myotonic indices of sexual response, this study demonstrates the significance of brain phenomena in sexual orgasm.

Adult↗